CERo Therapeutics, Inc.

Cero Therapeutics is a biotechnology startup based in the United States that was founded in 2017. The company’s slogan, "Tumor Cell Clearance Reimagined," reflects its core mission of revolutionizing cancer treatment through innovative therapies. At Cero, the focus is on expanding the armamentarium of engineered cell therapies to create a new class of medicines for oncology. Their approach involves leveraging an understanding of cellular clearance and molecular immunology to engineer cells that engage new and complementary cell elimination pathways, enabling deeper and more sustained clinical responses to maximize wellness. In March 2020, Cero Therapeutics secured a significant $40.00M Series A investment from prominent investors including Arch Venture Partners, Altitude Life Sciences, Lyell Immunopharma, and Sequoia China. This strong investor interest showcases confidence in the startup’s potential to make a meaningful impact in the biotechnology and oncology fields. The backing from established venture capital firms further validates Cero Therapeutics' innovative approach and signifies a milestone in their journey towards developing groundbreaking treatments for cancer.